Member Info for kopfkissen

Didn't even wait to see if we are on the list or not, just dropped from the start

I agree tommyscope - every large after hours trade is always trumpeted as 'large buy' even though if you look at the time of the trade and the buy/sell prices at the time it is often screamingly obvious it was a sell!

A completely off the wall choice, BZT. Very cheap so you can get lots of shares for not much and could, with some luck, multibag.

This is very intruiging:
"On question 1
Approve the Company's deal.
The decision was taken unanimously".
So now the deal has been unanimously approved by NN, presumably EUA will feel able to confirm it tomorrow, IF INDEED IT IS US ! I really REALLY hope it is !!!!! (that's from a person who hates multiple exclamation marks).

Link doesn't work

It wouldn't, but I thought the nature of the deal and who it was with might be mentioned.

No RNS about this, and sp falling, so presumably this was another red herring as surely NN could not make this public without an accompanying RNS from EUA.
Unless of course we get an RNS in the next few hours ...

Dropped the bid by half a penny in the last second of trading !!!

Not sure i believe this. The whole point of sticking money into a sipp is to avoud CGT. Where did this info come from ?

Sorry, Ragsbob not Ramsbottom!!

Ramsbottom- "Hi so just found out that if Norlisk Nickel is the new purchaser of EUA my Hargreaves Landsdown sipp and Isa is not covered in the tax free rapper which is a bit of a bummer. CGT would be charged on any gains when cashed out". What ?? Where did this info come from ? If your EUA shares are in an HL SIPP (as mine are) then there is no CGT to pay when company is sold.

Part 2 :

Another contract published last week shows that the government spent more than £1.35m to fly lateral flow tests from China to the UK, although it did not disclose further details.

“We’ve yet to find a UK-based lateral flow test that’s good enough,” according to a person directly involved in the validation process

The Innova tests, expected to play a main role in the Liverpool trial, were found to have 100 per cent specificity, avoiding false positives, and 96 per cent sensitivity, avoiding false negatives, in clinical trials.

However, the company’s instructions state that the tests can pick up infections from people “who are suspected of Covid-19 by their healthcare provider within the first five days of the onset of symptoms” and that they are designed for use by trained healthcare and laboratory staff.

“The Innova test is not approved for community use,” said Jon Deeks, professor of biostatistics at Birmingham university. “This is dangerous and not how science should proceed.”

One person close to the validation process said that some field studies of the tests in community settings, such as universities, had produced poorer results than others, indicating the need for robust training.

The different testing technologies

The government has mostly focused its investment on four testing technologies.

While the gold-standard reverse transcription polymerase chain reaction (PCR) tests are highly accurate, they are time consuming to process and require lab equipment and clinical expertise to analyse. They allow scientists to take a sample containing a very small amount of virus RNA, convert it to DNA, and multiply it so it can be detected.

Limited lab capacity and problems with the supply of reagents have meant that turnround times have remained stubbornly high for RT-PCR testing, with fewer than one in four results returned within 24 hours, contrary to what Mr Johnson promised in June.

Here you go,in two parts:

November 4, 2020 4:00 am by Anna Gross and Ian Bott in London

Boris Johnson has placed his faith in millions of cheap, reliable tests that provide results in minutes as a route out of future lockdowns caused by a resurgence of coronavirus.

Speaking a few hours before Tuesday’s announcement that Liverpool would be the first city in the UK to conduct population-wide testing for Covid-19, the prime minister declared that the quick turnround tests would “enable us to defeat this virus by the spring”.

As England prepares to enter its second national lockdown on Thursday, the government’s Operation Moonshot plan to deliver a mass population testing programme is back under the spotlight.

According to documents reviewed by the Financial Times, the Department of Health has awarded contracts worth at least £1bn to companies providing rapid testing. Many of the technologies relating to these contracts will feed into the Liverpool trial, in which everyone living or working in the city will be eligible for a test from Friday.

The strategy will hinge on new lateral flow tests, which give results in 20 minutes and can be performed on either a throat or a saliva sample, as well as conventional swab tests and loop-mediated isothermal amplification (Lamp) technology.

The pilot is expected to last about two weeks, with tests being deployed by the army, and could allow teachers, pupils and hospital staff to be tested weekly.

But scientists have raised concerns over the accuracy of some of the lateral flow tests being used, which are prone to missing cases of active infection. Meanwhile, delays in assessing technologies produced in the UK have led to frustration over government contracts being awarded to overseas companies.

Contracts

The government has so far signed at least 10 contracts with companies based in the UK, US and China, totalling more than £1bn, for rapid testing technology and logistics, according to publicly available contracts on the EU public procurement site, Ted, and information shared with the non-profit legal firm the Good Law Project.

The FT shared its calculations with the Department of Health, which declined to comment on the contracts, citing commercial sensitivity.

Despite a drive to turbocharge the UK diagnostics industry, the contracts show that the Department of Health spent £138m on millions of lateral flow tests produced by US company Innova, whose tests will be used in the Liverpool pilot.

It has spent more than £80m on two tests made by US companies Abbott and LumiraDX, which is also being offered by the pharmaceuticals retailer Boots, according to the documents. One person close to the procurement process said the government had also spent an unspecified sum on lateral flow tests produced by the Chinese company Zhejiang Orient Gene and the Korean medtech company SD Biosensor.

If you copy the link and paste it into a browser, instead of clicking it directly here, it seems to avoid the paywall. No idea why.

Better link :
www.google.com/amp/s/amp.ft.com/content/ff84d393-7c83-447b-810f-3f818b28d82c

https://www.google.com/amp/s/amp.ft.com/content/ff84d393-7c83-447b-810f-3f818b28d82c

Nm

I've a feeling it closed today at it's lowest price for a month.

Whats L2 doing ?

Yes, I'm 65. That's why I need this done and dusted so I can benefit before I lose my marbles.